Laurus Labs ' Nomination and Remuneration Committee has approved a comprehensive stock option grant across three Employee Stock Option Plans (ESOP), benefiting over 1,100 employees. The committee meeting held on January 23, 2026, sanctioned the distribution of 4,23,125 stock options at a uniform grant price of ₹754.50 per option.

Grant Distribution Across ESOP Schemes

The stock option allocation spans three distinct schemes with varying employee coverage:

Pricing and Effective Date

All options carry a face value of ₹2.00 each and are priced at ₹754.50 per option. This pricing represents a 25% discount to the market value of shares on the last trading day, January 22, 2026. The effective date for all grants is July 01, 2025, providing employees with participation in the company's performance through equity ownership.

Vesting Schedules

The vesting structure differs between the schemes. For the 2016 and 2018 ESOP schemes, options vest in three stages:

The 2021 ESOP scheme follows a four-stage vesting schedule with equal 25% distributions over five years, extending the final vesting to July 01, 2030.

Exercise Terms and Conditions

Employees must exercise their vested options within one year of the respective vesting dates. Options that remain unexercised beyond this period will lapse automatically. Each option, when exercised, converts into one fully paid-up equity share with a face value of ₹2.00.

The shares arising from option conversion will rank equally with existing equity shares and will not be subject to lock-in restrictions, except those imposed by applicable laws. This structure allows employees to participate directly in the company's growth while maintaining flexibility in their investment decisions.

Laurus Labs continues to witness significant institutional trading activity with another major block trade executed on the National Stock Exchange (NSE), demonstrating ongoing investor interest in the pharmaceutical company's shares.

Latest Block Trade Details

The recent transaction represents substantial institutional activity in the pharmaceutical sector, executed at competitive market rates.

Previous Trading Activity

This follows other significant block trades in Laurus Labs shares that occurred recently, showing sustained institutional interest in the company.

Market Implications

Block trades are typically executed by institutional investors, mutual funds, or other large market participants when they need to buy or sell substantial quantities of shares. These transactions are conducted outside the regular market to avoid significant price impact that could occur with large orders in the normal trading system.

The execution of this latest block trade at ₹1,063.70 per share, compared to previous trades at ₹1,065.70 and ₹1,068.00, indicates the price levels at which institutional investors continue to find value in Laurus Labs shares. Such transactions often reflect portfolio rebalancing activities or strategic investment decisions by large financial institutions.

About Block Trades

Block trades serve as an important mechanism in the Indian capital markets, allowing large investors to execute substantial transactions efficiently. These trades help maintain market stability by preventing large orders from causing excessive volatility in regular trading sessions. The continued block trade activity in Laurus Labs suggests sustained institutional confidence in the pharmaceutical company's prospects.